Basic Information
| LncRNA/CircRNA Name | ABHD11-AS1 |
| Synonyms | LINC00035, NCRNA00035, WBSCR26 |
| Region | NA |
| Ensemble | ENSG00000225969 |
| Refseq | NR_026690 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, other |
| Sample | PTC tissues and cell lines (K-1, TPC-1, and IHH-4) |
| Expression Pattern | up-regulated |
| Function Description | We found that ABHD11-AS1 was remarkably overexpressed in PTC, and high expression was related to tumor size, lymph node metastasis, extrathyroidal extension and advanced TNM stage. Moreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation. In addition, rescue assays were performed to confirm the ABHD11-AS1/miR-199a-5p/SLC1A5 axis. Taken together, the data show that ABHD11-AS1 acts as a competing endogenous RNA (ceRNA) to exert malignant properties in PTC through the miR-199a-5p/SLC1A5 axis. Therefore, our study may shed light on PTC diagnosis and therapies. |
| Pubmed ID | 31409775 |
| Year | 2019 |
| Title | Long Noncoding RNA ABHD11-AS1 Functions as a Competing Endogenous RNA to Regulate Papillary Thyroid Cancer Progression by miR-199a-5p/SLC1A5 Axis |
External Links
| Links for ABHD11-AS1 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |